Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Pilar García‐Alfonso et al.|The Lancet|2023Cited by 319
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav et al.|Nature Communications|2023Cited by 159
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysisSeiichiro Mitani, Kei Muro, Shigenori Kadowaki et al.|Cancer Medicine|2019Cited by 23